麻豆传媒

Antonio Giordano, MD, PhD, is an oncologist and geneticist, as well as founder and president of the Sbarro Health Research Organization and director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University in Philadelphia, Pennsylvania. He works on molecular therapeutics and also studies the connections between obesity and cancer. Antonio Giordano grew up in Naples, Italy, where his father, Giovan Giacomo Giordano, was an oncologist and pathologist at the National Cancer Institute of Naples and a professor at the University of Naples. Giordano decided to branch out and start a career in research that was more oriented towards genetics applied to pathology. Early on, while following his father's research, he became interested in the link between the effect of toxic waste on the environment and the increasing cancer rates in the Campania region in Italy. Giordano earned his medical degree at the University of Naples in 1986, and his doctorate at the University of Trieste in 1990. He has published over 600 papers on gene therapy, cell cycle, genetics of cancer, and epidemiology. His early research includes seminal work done in 1989, demonstrating the importance of cell cycle proteins in the functioning of DNA tumor viruses. The transforming gene products of these viruses, such as the E1A oncoproteins of adenovirus 5, led to the identification of cellular factor p60, known as cyclin A. This research was the first demonstration of a physical link between cellular transformation and the cell cycle, thereby paving the way for the melding of these two areas of research. It also helped to open a very exciting avenue of research involving investigators with expertise in different aspects of growth control and cancer.Giordano’s lab also discovered the tumor suppressor gene RB2/p130 and the cell cycle kinases CDK9 and CDK10, two other key players in cell cycle regulation and cell differentiation. Antonio Giordano is the recipient of the Irving J. Selikoff Award for Cancer Research, the Rotary International Award, and Lions Club Napoli-Europa. He has also received the title of Knight of the Republic and Commander of the Order of Merit of the Italian Republic. At the 25th anniversary of the National Organization of Italian American Women, he was awarded the Cross of Merit Melitense, an honor of the Sovereign Military Order of Malta. www.shro.org www.drantoniogiordano.com

Dr. Mielcarek believes that individualizing treatment according to the patient's needs and philosophy, combined with incorporating up-to-date research knowledge, are key ingredients for excellent patient care.
Clinical Expertise

    Blood stem cell and bone marrow transplantation for hematologic malignancies
    Graft-versus-Host Disease (GVHD)

Title

    Medical Director, Adult Blood and Marrow Transplant Program, Seattle Cancer Care Alliance
    Member, Clinical Research Division, Fred Hutch
    Professor of Medicine, Department of Medical Oncology, University of Washington

Education and Training

    MD: Freie Universit盲t Berlin, 1986
    PhD: Freie Universit盲t Berlin, 1987
    Residency: Freie Universit盲t Berlin, Internal Medicine, 1987-1993
    Research Fellowship: Fred Hutchinson Cancer Research Center, 1994-1999
    Residency: University of Washington, Internal Medicine, 1999-2000
    Fellowship: University of Washington, Medical Oncology, 2000-2003

Dr. Brian Anderson is a Harvard-trained physician-scientist, innovator, and digital health expert. Dr. Anderson鈥檚 focus is on the use of information technology in support of emerging clinical decision support (CDS) models and the provision of safe, effective, patient-centered care. 
While at Athenahealth, where he led the Informatics Department, Dr. Anderson launched a new model of CDS leveraging Artificial Intelligence (AI). He has served on several national health information technology committees in partnership with the Office of the National Coordinator (ONC). 
At MITRE, Dr. Anderson works on mCODE, a standardized data language and interoperability model for cancer research and treatment, as well as architecting, implementing, and analyzing health information systems for the Centers for Medicare and Medicaid Services (CMS), the Department of Health and Human Services (HHS), and the Department of Veterans Affairs (VA). He also sits on the ONC鈥檚 Health Information Technology Advisory Committee.
Dr. Anderson has written in the Journal of Precision Medicine and spoken at the Precision Medicine Summit and HIMSS19. 

Maria C.E. Jacobs, M.D., leads the Radiation Oncology team at Mercy Medical Center in Baltimore, Maryland. She places top priority on quality patient care, medical excellence and helping her patients get the best possible radiation therapy treatment. Dr. Jacobs brings passion, enthusiasm and a heart for caring to her patients. In her role as Director of Radiation Oncology at Mercy, Dr. Jacobs oversees all radiation therapy and radiotherapy services for the hospital.

Dr. Maria Jacobs works in close collaboration with the cancer surgeons in The Breast Center at Mercy to coordinate post-surgical treatment for breast cancer patients. Intraoperative Radiotherapy (IORT) is a state-of-the-art technology that allows patients to get treated in one single radiation therapy session 鈥� a notable advantage over the many multiple visits required prior to IORT.

Patients are afforded other advantages because of the single session IORT treatment. Preservation of more healthy tissue and reduced side effects from the radiation are benefits many patients experience.

Dr. Jacobs and Dr. Neil Friedman, Medical Director at The Breast Center, were the first team of doctors in the state of Maryland to use Intraoperative Radiotherapy (IORT).

Dr. Jacobs and her team of Radiation Oncology specialists also use TrueBeam鈩� technology for the delivery of targeted radiation. This safe, faster, more precise cancer treatment option represents an immense leap forward in the speed and accuracy in which the radiation can be delivered. Dr. Jacobs sees this as a decided advantage for most patients. Cancer cells are attacked by an aggressive beam of radiation while minimizing the impact on surrounding tissue.

Dr. Jacobs beams with pride when she talks about the advances that have been made in radiation technology, treatment plans, and research. But like most top-rated doctors, Dr. Jacobs believes treating the patient means more than treating the disease. It鈥檚 about caring for the person鈥�that unique, one-of-a-kind individual who has family and friends, hopes and dreams 鈥� and a life beyond cancer.

The Mercy spirit surrounds you when you鈥檙e anywhere near Dr. Jacobs. She laughs easily, hugs abundantly and shares her vast depth of knowledge with patients and their families in the most engaging way.

Vadim Gushchin, M.D., serves as Director of The Melanoma and Skin Cancer Center at Mercy as well as Director of Gastrointestinal Oncology, a division of Surgical Oncology at Mercy Medical Center in Baltimore, Maryland. Dr. Gushchin offers expertise in complex malignancies and is a skilled cancer surgeon. He is exceptionally accomplished in minimally invasive surgery – most notably in da Vinci Robotic Surgery – as well as in traditional open surgery techniques. Gastrointestinal Cancer (GI Cancers), melanoma – more commonly known as skin cancer, and thyroid cancer are among the many cancer diagnoses Dr. Gushchin treats. To determine the best treatment option for his surgical oncology patients, Dr. Gushchin carefully evaluates each patient’s risk factors, medical history, current clinical condition, surgical alternatives and post-surgical recovery options in order to fully develop a thorough, personalized care plan. Dr. Gushchin comforts and compassionately walks his patients through the treatment steps needed to care for melanoma, thyroid and parathyroid disease, peritoneal surface malignancies (abdominal tumors), and recurring tumors within the colon, rectum and liver. Dr. Gushchin is well-recognized for his experience in treating complex cancers with HIPEC (Hyperthermic Intraperitoneal Chemotherapy). Dr. Gushchin trained under the internationally renowned surgical oncologist Dr. Paul Sugarbaker to master this procedure, which involves cytoreductive surgery followed by a heated chemotherapy solution to reduce and eliminate tumors. Dr. Gushchin has participated in over 150 HIPEC surgeries and provides patients expertise in complicated HIPEC surgeries including repeat HIPEC surgeries, simultaneous liver resections at the time of HIPEC as well as other advanced surgical treatments in conjunction with HIPEC treatment. An international presenter and teacher, Dr. Gushchin has educated physicians around the world on HIPEC treatment and has organized teaching courses for the treatment of peritoneal surface malignancies (complex abdominal cancers that can be treated with HIPEC). As an extension of his knowledge and compassion, Dr. Gushchin has been instrumental in setting up treatment centers for peritoneal surface malignancies in other parts of the world including Lithuania, Siberia and Ukraine. Dr. Vadim Gushchin is one of Mercy Medical Center’s top surgical oncologists. He utilizes many of the latest innovations in technology and research to provide state-of-the-art treatment options to his patients. Dr. Gushchin brings expertise in robotic surgery, using the da Vinci robot. Patients who qualify for da Vinci robot surgery typically experience the benefits of a more precise and exacting surgery, a less invasive procedure, shorter hospital stay and faster recovery. Dr. Vadim Gushchin leads a multidisciplinary team of experts at The Melanoma and Skin Cancer Center at Mercy to treat a wide range of skin cancers. As an experienced oncology surgeon and talented cancer specialist, he uses the Isolated Limb Infusion technique to try to save an arm or leg that has been aggressively attacked by skin cancer. Isolated Limb Infusion, also known as ILI, offers patients a remarkable alternative approach to metastatic melanoma on a limb. This type of skin cancer commonly leads to amputation or a disfiguring result. Dr. Gushchin and his patients know this doesn’t always have to be the case. Isolated Limb Infusion gives Dr. Gushchin a fighting chance to save his patients’ affected arms and/or legs, reduce or shrink the cancerous tumor and avoid the need for a more radical surgery.

Dr. Priyanka Sharma is an oncologist in Fairway, Kansas and is affiliated with University of Kansas Hospital. She received her medical degree from Baroda Medical College and has been in practice between 11-20 years.

Her specialties are: oncologists diagnose and treat cancers of all types. They use diagnostic tools like biopsies, endoscopies, X-ray and other imaging, nuclear medicine, and blood tests. Cancer surgeons, or surgical oncologists, remove tumors, while medical oncologists treat cancers with chemotherapy. Radiation oncologists use multiple forms of radiation in an effort to eliminate tumors.

Debashish Bose, M.D., PhD, FACS, an experienced, well-respected surgeon, serves as Medical Director of The Center for Hepatobiliary Disease at Mercy as well as Associate Director of Surgical Oncology at Mercy in Baltimore, Maryland. He is Board Certified in General Surgery and offers particular expertise in advanced surgical techniques for pancreatic cancer and liver cancer.

Dr. Bose provides leading edge cancer treatment options, including minimally invasive and robotic surgery in the care of late-stage and complex oncologic disease. He and his colleagues treat benign and malignant tumors in the peritoneal and abdominal cavity, including:

路         Stomach and Gastrointestinal Tract Tumors and Cancer

路         Pancreatic and Neuroendocrine Tumors

路         Soft Tissue Sarcoma

路         Metastatic Colon Cancer

路         Liver Tumors

路         Adrenal Gland Cancer

Dr. Bose works in close collaboration with the liver and pancreatic experts at Mercy鈥檚 Institute for Digestive Health and Liver Disease to provide patients the best possible outcome for their diagnosis.

Mercy Medical Center鈥檚 renowned surgical oncologists teamed with the experience of its liver and pancreatic experts provide patients seeking care for pancreatic cancer one of the most comprehensive gastrointestinal cancer teams in the Mid-Atlantic region.

In addition to offering surgical expertise, Dr. Bose aims to provide cancer patients with the knowledge and information needed for them to better understand their specific diagnosis, treatment and outcomes. He has dedicated his career to becoming an ally and a resource for patients facing late-stage and complex cancers. He guides patients through the treatment process and helps them make decisions to optimize their care and regain hope for a better quality of life.

Second opinion consultation and collaborative care with partner physicians make Dr. Bose a trusted expert among both patients and colleagues. Gastroenterologists, medical oncologists and primary care physicians rely on Dr. Bose for his insights, surgical skill and commitment to improving cancer survival.

Dr. Debashish Bose actively participates in research and has been the recipient of the Ruth L. Kirschstein National Research Service Award (NRSA). He has served as Principle Investigator in studies related to pancreatic cancer. His work has been published in peer-reviewed articles, book chapters and abstracts, and he has made numerous presentations to foster clinical advances in surgical oncology.

Education & Fellowships

路         Fellowship: University of Texas MD Anderson Cancer Center

路         Residency: Johns Hopkins Hospital

路         Medical Degree: University of Maryland School of Medicine

The human body is teeming with internal fauna. There are an estimated 10鈥�100 trillion additional cells in this mass of microbes 鈥� roughly equal to the number of human cells in our bodies 鈥� and they are found everywhere, including the breast. Sharma will focus on one such microbe, Bacteroides fragilis, the presence of which in the breast, gut and mammary tissue is linked to a particularly aggressive form of breast cancer.

Dr. Teplinsky is a board-certified medical oncologist specializing in breast and gynecologic oncology. She is the head of breast and gynecological medical oncology at Valley-Mount Sinai Comprehensive Cancer Care in Paramus, New Jersey, and a clinical assistant professor of medicine at the Icahn School of Medicine at Mount Sinai in New York.









Her clinical and research interests focus on young women with breast cancer, survivorship, exercise oncology, and the use of social media in oncology. She is passionate about oncology education and advocacy on social media and is the host of the INTERLUDE Podcast, where she shares the stories and experiences of those who have been affected by cancer. The podcast provides support, inspiration, encouragement, hope, and strength to others who are going through similar experiences.
You can also follow Dr. Teplinsky's work and advocacy on  and .

Michael Leapman, MD was drawn to the field of urology for the opportunity to care for patients with urologic cancers. He aims, above all, to deliver the highest level of care possible with the utmost consideration and compassion for the impact that cancer places on patients, as well as their families, friends and communities.
Dr. Leapman graduated from Cornell University where he majored in Neurobiology and Behavior, and received his medical school degree from the University of Maryland in Baltimore. He completed his General Surgery and Urology training at the Mount Sinai Hospital in New York, NY. Subsequently, he completed a urologic oncology fellowship at the University of California San Francisco (UCSF) accredited by the Society of Urologic Oncology. He joined the faculty at the Yale University School of Medicine and Yale Cancer Center in 2016, specializing in urologic oncology with a joint appointment at the West Haven Veterans Affairs Medical Center.

Danielle M. Alm, PharmD, BCPS, BCPPS, is an Associate Professor of Clinical Pharmacy at the Philadelphia College of Pharmacy (PCP). Additionally, she is a Pediatric Clinical Pharmacy Specialist at Children鈥檚 Regional Hospital at Cooper University HealthCare. In this role she practices in general pediatrics as well as pediatric intensive care unit patients. Here, Dr. Alm precepts learners, including introductory and advanced pharmacy practice experience (IPPE) and (APPE) students and a PGY2 Pharmacotherapy Resident.

On campus, Dr. Alm鈥檚 didactic teaching responsibilities include pediatric content taught throughout the curriculum. Pediatric content includes pediatric infectious diseases, pharmacokinetic and pharmacodynamic differences, pediatric enteral and parenteral nutrition, pediatric seizures, multiple sclerosis, drug information and literature evaluation, and hematology and oncology. She also coordinates the pediatric elective. Dr. Alm鈥檚 research interests include student run research, pediatric research focusing on medication safety, pharmacodynamics, and asthma. She is an active member of the Pediatric Pharmacist Association (PPA) where she has served in many different roles.

Mehra Golshan, MD, MBA, is a cancer surgeon and a nationally and internationally recognized leader in breast cancer treatment and research. In addition to caring for patients, he serves as Deputy Chief Medical Officer for Surgical Services and Clinical Director of the Breast Cancer Program for the Yale Cancer Center, Smilow Cancer Hospital, and Smilow Cancer Hospital Care Centers.
Dr. Golshan also serves as the Executive Vice Chair for Operations in the Department of Surgery and Professor of Surgical Oncology at the Yale School of Medicine.
Dr. Golshan is a leader in the research with over 150 peer reviewed publications. He has led numerous Phase I, II and III clinical trials and translational science innovations impacting the treatment options and outcomes for women. He is an innovator in tailoring surgery and therapy for women with early stage breast cancer with funding support from the Breast Cancer Research Foundation and National Institutes of Health. He is the principal investigator of several phase II trials aiming to reduce the need for second surgeries or re-excisions in women with breast cancer, one of which uses innovative image-guided operating room capabilities to capture and remove all residual tumor utilizing MRI and mass spectrometry which is used at Yale鈥檚 hybrid operating room.
Dr. Golshan prides himself on being an educator having trained and mentored over a hundred breast surgical fellows as well as international surgeons. He has lectured and taught surgeons, trainees and students nationally and internationally in the field of oncology and breast cancer treatment.
Dr. Golshan is a Board Member of the National Accreditation Program for Breast Centers (NAPBC), Chair of NAPBC Education Committee, Chair of the American College of Surgeons Committee on Interprofessional Education and Practice, and Chair of the American Society of Breast Surgeons Question of the Week Committee.
Dr. Golshan completed his fellowship in breast surgical oncology at Northwestern Memorial Hospital. He earned his Medical Degree from Case Western Reserve University School of Medicine and an MBA at Massachusetts Institute of Technology, Sloan School of Management in Cambridge Massachusetts.
Prior to joining Yale, he spent 17 years in Boston at Harvard鈥檚 Brigham and Women鈥檚 Hospital, Dana Farber Cancer Institute where he was the inaugural and incumbent Dr. Abdul Mohsen and Sultana Al-Tuwaijri Distinguished Chair in Surgical Oncology. He also served as the Director of the Breast Surgical Oncology Fellowship at the Dana-Farber Cancer Institute/Brigham and Women鈥檚 Hospital/Massachusetts General Hospital and was an Associate Professor of Surgery at Harvard Medical School.
Dr. Golshan鈥檚 approach to breast cancer treatment is through a specialized team approach. For each new patient, Smilow brings together a team of medical oncologists, radiation oncologists, reconstruction surgeons, pathologists, genetics, breast imagers, radiologists, program nurses, and a robust clinical research program. 鈥淚 work closely with so many colleagues dedicated deeply to treating and curing breast cancer who inspire me to be a better physician, scientist, and person every day."

Education & Training
MBA
MIT (2019)
Fellow
Northwestern Memorial Hospital (2003)
Resident
Rush Presbyterian St. Luke's Medical Center (2002)
MD
Case Western Reserve University (1996)

Dr. Greenup is an Associate Professor of Surgery (Oncology) and Chief of Breast Surgical Oncology. She provides coordinated, state-of-the-art care to patients with benign and malignant diseases of the breast as part of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center.
Learn more about Dr. Greenup
She earned her undergraduate degrees in Zoology and Psychology at the University of Wisconsin, where she also completed a Master of Public Health. She received her medical degree from the Medical College of Wisconsin where she also completed her General Surgery residency, and went on to complete a fellowship as part of The Massachusetts General Hospital, Dana-Farber Cancer Institute and Brigham and Women's Hospital Breast Surgery Fellowship.
Prior to joining Yale, Dr. Greenup was an Associate Professor of Surgery and Population Health Sciences at the Duke University School of Medicine and Duke Cancer Institute. There she founded the Duke Breast Cancer Outcomes Research Group, and Core Faculty for the Duke Margolis Center for Health Policy. In 2016, she received the National Institutes of Health Building Interdisciplinary Research Careers in Women鈥檚 Health (BIRCWH) Award to evaluate how financial costs and burden relate to preference-sensitive decisions for breast cancer surgery. In 2017, she was named the American College of Surgeons and the American Society of Breast Surgeons Health Policy Scholar. Her research focuses on aligning patient-centered care with high-quality, lower cost treatment. She serves on several national committees, including the Alliance in Clinical Oncology Ethics and Value Committees, the American College of Surgeons Cancer Care Delivery Task Force, the American Society of Breast Surgeons Legislative Committee, and the Editorial Board for the Annals of Surgical Oncology.

Education & Training
MD
Medical College of Wisconsin (2009)
MPH
University of Wisconsin (2009)

Dr. Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed a residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). As a medical oncology fellow during his training at MSKCC, Dr. Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T-cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T-cell receptors termed chimeric antigen receptors (CARs). Following the completion of his medical oncology training, Dr. Brentjens became the principal investigator of his own laboratory. As a PI, Dr. Brentjens successfully translated these studies to the clinical setting treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T-cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of “armored CAR T-cells” currently being translated to the clinical setting as second-generation CAR modified T-cell clinical trials. Additionally, work in the Brentjens’ lab has expanded this CAR technology to target additional tumor antigens expressed on other malignancies including solid tumors. Positions Roswell Park Comprehensive Cancer Center Deputy Director Professor of Oncology Chair, Department of Medicine Department of Immunology The Katherine Anne Gioia Endowed Chair in Cancer Medicine Jacobs School Of Medicine And Biomedical Sciences, State University of New York at Buffalo Professor of Medicine Background Education and Training: 1996 - MD - The State University of New York at Buffalo, Buffalo, NY 1996 - PhD - Microbiology and Immunology, The State University of New York at Buffalo, Buffalo, NY 1989 - BA - History, Davidson College, Davidson, NC Residency: 1996–1998 - Intern/Resident, Department of Internal Medicine, Yale New Haven Hospital, New Haven, CT Fellowship: 1998–2002 - Hematology and Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 1998–2002 - Department of Medicine, Weill Cornell Medical College (WCMC), New York, NY Board Certification: American Board of Internal Medicine (ABIM), Medical Oncology 2019-2021 - NYS DOH Cert. of Qualification (Cellular Immunology) Professional Memberships: 2018–present - Member, American Society of Bone Marrow Transplant (ASBMT) 2016-present - Member, American Society of Hematology (ASH) Media Experts Subcommittee 2016–present - Member, European Academy for Tumor Immunology 2015–present - Member, American Society for Clinical Investigation (ASCI) 2014–present - Member, International Society for Cellular Therapy (ISCT) 2015–present - Member, Society for Immunotherapy of Cancer (SITC) 2013–present - Member Society of Hematologic Oncology (SOHO) 2015–present - Member, European Society for Gene and Cell Therapy (ESGCT) 2015–present - Member, European Hematology Association (EHA) 2015–present - Member, American Association of Immunologists (AAI) 2015–present - Member, European Society for Gene and Cell Therapy (ESGCT) 2014–present - Member, Interurban Clinical Club 2011-present - American Association for Cancer Research (AACR) 2009-present - Member, New York Academy of Sciences (NYAS) 2002-present - Member, International Society of Analytical Cytology (ISAC) 2002-present - Member, American Society of Gene and Cell Therapy (ASGCT formerly ASGT) 2000-present - Member, American Society of Hematology (ASH) 1999-present - Member, American Society of Clinical Oncology (ASCO) 1997-present - Member, American College of Physicians (ACP) 1991-1995 - Member, American Society of Microbiology Honors & Awards: 2014 - NY Intellectual Property Law Association Inventor of the Year Award, New York Intellectual Property Law Association 2014 - Emerald Foundation Outstanding Investigator Award, Emerald Foundation 2014 - Distinguished Lecturer Award, Society of Hematological Oncology 2013 - Sir William Osler Young Investigator Award, Interurban Club 2009 - Outstanding New Investigator Award, American Society of Gene Therapy 2006-2011 - Damon Runyon Clinical Investigators Award, Damon Runyon 2005-2008 - Amgen Career Development Award, Amgen 2004 - Clinical Scientist Development, Memorial Sloan Kettering Cancer Center 2001 - Doris Duke Fellows Award Recipient for Translational Research, Doris Duke Charitable Foundation 2000-2002 - Cure for Lymphoma (CFL) Research Grant Award Recipient, Cure for Lymphoma Foundation

Assistant Professor of Oncology
Department of Immunology
Education and Training:
2013 - Ph.D. - Biological Sciences, State University of New York at Buffalo
Professional Memberships:
The American Association of Immunologists
Radiation Research Society
American Urological Association
Society for Basic Urologic Research
Honors & Awards:
2021 - Chair, Radiation and Anti-tumor Immunity Session, Radiation Research Society
2019 - Chair, Understanding Immune Responses to Cancer, Upstate NY Immunology Conference
2018 - Early Career Investigator Travel Award, Radiation Research Society
2018 - Chair, Cell Therapies Session, Translational Research Cancer Centers Consortium
2014 - Best Poster, Northeastern Section of the American Urological Association
2013 - Travel award, Midwest Melanoma Partnership
2012 - The American Association of Immunologists Young Investigators Award, Upstate New York Immunology Conference
2012 - Junior Investigator Award, Translational Research Cancer Centers Consortium Meeting
2011 - 1st Place New Investigator Travel Award, Society for Thermal Medicine
Research
Research Overview:
The goal of my laboratory is to elucidate the molecular mechanisms that limit renal cell carcinoma patient responses to immunotherapy. The laboratory鈥檚 translational studies are concentrated on enhancing anti-tumor immunity through improved myeloid cell function and cytolytic T cell activity within renal cell carcinoma. Our laboratory鈥檚 findings from a pilot trial in metastatic renal cell carcinoma combining high-dose radiation of kidney tumors with surgical resection, provide a glimpse into the immune activating effects of radiation in human cancer. The laboratory鈥檚 most recent studies performed in collaboration with Dr. Scott Abrams shed light on the role key transcription factors at play in macrophage behavior and patient outcome.


Publications
Chow J, Hoffend NC, Abrams SI, Schwaab T, Singh AK, Muhitch JB. Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients. Proc Natl Acad Sci U S A. 2020 Sep 8;. doi: 10.1073/pnas.2001933117. [Epub ahead of print] PubMed PMID: 32900949.
Muhitch JB, Hoffend NC, Azabdaftari G, Miller A, Bshara W, Morrison CD, Schwaab T, Abrams SO. Tumor-associated macrophage expression of interferon regulatory Factor-8 (IRF8) is a predictor of progression and patient survival in renal cell carcinoma. J Immunther Cancer. 2019; 7: 155.
Singh AK, Winslow T, Habiby Kermany M, Goritz V, Heit L, Miller A, Hoffend NC, Stein LC, Kumaraswamy LK, Warren GW, Bshara W, Odunsi KO, Matsuzaki J, Abrams SI, Schwaab T, Muhitch JB. A pilot study of stereotactic body radiation therapy combined with cytoreductive nephrectomy for metastatic renal cell carcinoma. Clin Cancer Res. 2017; 23: 5055-5065.
Ku A, Muhitch JB, Diehl M, Abrams SI, Ostrand-Rosenberg S, Evans SS. Myeloid-derived suppressor cell-mediated downregulation of L-selectin limits T cell trafficking in lymph nodes which can be alleviated by systemic thermal therapy. eLife. 2016; 5:e17375.
Battaglia S and Muhitch JB. Unmasking targets of antitumor immunity via high-throughput antigen profiling. Curr Opin Biotechnol. 2016; 42: 92-97.
Fisher D, Muhitch JB, Kim M, Doyen K, Bogner P, Evans SS, Skitzki J. Intraoperative intravital microscopy permits the study of human tumour vessels. Nat Commun. 2016; 7: 10684.
Mikucki M, Fisher D, Matsuzaki J, Skitzki JJ, Gaulin N, Muhitch JB, Frelinger J, Odunsi K, Gajewski T, Luster A, Evans SS. Non-redundant requirement for CXCR3 signalling during tumoricical T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015; 6: 7458.
Muhitch JB and Schwaab T. High-dose interleukin-2 (IL-2) for metastatic renal cell carcinoma: can the first anti-tumor immunotherapy be reinvented? Immunotherapy. 2014; Sep 6; (9): 955-958.

Dr. Gibson (nee Quinn) is an Endocrine Surgeon and Associate Professor of Surgery at Yale School of Medicine. Her clinical interests are surgery of the thyroid, parathyroid and adrenal gland, including minimally-invasive laparoscopic and retroperitoneoscopic surgical techniques. In addition, she serves as the Associate Clerkship Director for the Yale School of Medicine General Surgery Clerkship and is the Fellowship Director of the Endocrine Surgery Fellowship Program.
Her research interests include outcomes after minimally-invasive endocrine surgery (thyroid, parathyroid, adrenal), outpatient thyroidectomy and parathyroidectomy, intraoperative laryngeal nerve monitoring, and endocrine oncology. She obtained her MD from Virginia Commonwealth University School of Medicine, Richmond, VA. She was a postdoctoral research fellow in In Utero Stem Cell Transplantation at The Children's Hospital of Philadelphia (CHOP), Philadelphia, PA. She completed her training in General Surgery at Saint Barnabas Medical Center, Livingston, NJ, and Endocrine Surgery at Scott and White Memorial Hospital, Temple, TX.

---

Dr. Partridge received her MD from Cornell University Medical College in 1995. She completed her residency in internal medicine at the Hospital of the University of Pennsylvania and went on to complete fellowships in medical oncology and hematology at DFCI, MGH and BWH. She also received an MPH from Harvard School of Public Health. She is a medical oncologist who cares for adults with breast cancer, with a particular focus on the unique needs of young patients with breast cancer.  She also leads efforts to optimize cancer survivorship care and research at DFCI.

Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Medical Director, International Strategic Initiatives at Dana-Farber and past President of the Medical Staff at DFCI (2016-2018). He received the George Canellos Award for Excellence in Clinical Investigation and Patient Care from DFCI in 2013, the Eugene Schonfeld Award from the Kidney Cancer Association (KCA) in 2016, and is a 2021 Giants of Cancer Care inductee. He serves on the National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel, KidneyCan Board, the National Cancer Institute (NCI) GU Steering Committee, and is past Chairman (2015-2018) of the Medical and Scientific Steering Committee of the KCA. Dr. Choueiri is an elected member of the American Society of Clinical Investigation (ASCI). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania.
Dr. Choueiri is interested in developing novel experimental therapies and biomarkers in GU malignancies, including renal cell carcinoma (RCC). In a series of New England Journal of Medicine (NEJM) articles on which he was either first or senior author, Dr. Choueiri and colleagues have made seminal observations that have defined and evolved the treatment of metastatic RCC and led to the approval of several therapies such as Cabozantinib, Pazopanib, Avelumab+Axitinib, Cabozantinib+Nivolumab, and Pembrolizumab+Lenvatinib, as well as adjuvant pembrolizumab. His research also focuses on the epidemiology, diagnosis, and treatment outcomes of GU cancers, especially through having co-established the International Metastatic RCC Database Consortium criteria for RCC risk stratification. His biomarker work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy. He has also contributed to our understanding of the underlying biology and rationale for therapies in rare histological variants of RCC such as papillary, translocation, and sarcomatoid RCC.
Dr. Choueiri has received research funding from the NCI, the Department of Defense (DOD), the American Society of Clinical Oncology (ASCO), and industry partners. His work has been published in journals such as the NEJM, Nature, Nature Medicine, Science, Cancer Cell, Journal of American Medical Association (JAMA), JAMA Oncology, The Lancet, Lancet Oncology, and Journal of Clinical Oncology. He lectures frequently throughout the United States and around the world. He has over 675 PubMed-indexed publications and is the lead investigator of multiple national and international phase I-III trials in GU cancers.

Dr. Jorge Nieva graduated from the University of California, Irvine College of Medicine in 1997, trained in internal medicine at University of California, San Diego and in oncology and hematology at the Scripps Clinic. In 2003 he joined the faculty of the Scripps Research Institute and the medical staff of the Scripps Clinic in La Jolla, CA. While at Scripps, Dr. Nieva pioneered new technology for the detection of cancer cells in the peripheral blood and discoveries related to the fundamental mechanisms of the immune system.
Dr. Nieva was recruited to the Billings Clinic in Montana in 2007 where he served as department chair and was a program leader who established the multidisciplinary lung cancer and head/neck cancer clinics at the cancer center. While in Billings, Dr. Nieva led efforts to establish a research program in virus-delivered cancer gene therapy and immunotherapy. His teams were awarded certificates for excellence in the conduct of cancer clinical trials from the National Cancer Institute and the American Society of Clinical Oncology. Dr. Nieva returned to California, joining the faculty of the Keck School of Medicine in 2014.